Safety of Moxifloxacin as Shown in Animal and In Vitro Studies

作者
David H. McGee,William F. Holt,Philip R. Kastner,Rebecca L. Rice
出处
期刊:Survey of Ophthalmology [Elsevier BV]
卷期号:50 (6): S46-S54 被引量:30
标识
DOI:10.1016/j.survophthal.2005.05.003
摘要

Topical treatment of ocular bacterial infection is practiced widely, and the choice of the antibacterial agent depends on the nature of the infection, including the susceptibility of the organism, the tissue affected, and the safety profile of the agent. Moxifloxacin is a fourth-generation fluoroquinolone approved for ophthalmic use as moxifloxacin ophthalmic solution 0.5% (VIGAMOX, Alcon, Fort Worth, TX). Moxifloxacin ophthalmic solution 0.5% is self-preserved at a near-neutral pH of 6.8. In treating ocular infection, the three important aspects of therapeutic control are potency, penetration of the drug to the target site, and safety of the drug and the drug product. Moxifloxacin ophthalmic solution 0.5% provides antibacterial potency and high penetration of target ocular tissues. The ocular and systemic safety profile of moxifloxacin compares favorably with those of other fluoroquinolone antimicrobial agents, with a low risk of recognized quinolone-related toxicity. In vitro studies of fluoroquinolones with human or rabbit corneal epithelial cells or keratocytes suggest that moxifloxacin is similar in cytotoxicity potential to other drugs of this family. Specialized in vivo corneal wound-healing studies draw little distinction between moxifloxacin-treated eyes and those treated with other fluoroquinolones. Repeated-dose topical ocular studies in rabbits and monkeys, with high concentrations (up to 3%) of moxifloxacin and at treatment durations and regimens well in excess of label-prescribed use, demonstrated a high safety margin for ocular and extraocular tissues. Cornea, the tissue with highest exposure, was found to be unaffected by these high exposures, with slit-lamp biomicroscopy, corneal thickness measurement, intraocular pressure, and specular microscopy of the corneal endothelium (monkeys only), and histologic evaluation showing no effects, as compared with controls. Moxifloxacin ophthalmic solution 0.5% affords superior efficacy and ocular tissue penetration, with a favorable safety profile.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
务实的夏菡完成签到 ,获得积分10
2秒前
123455完成签到,获得积分10
4秒前
丘比特应助虚拟的柜子采纳,获得10
5秒前
Beata完成签到,获得积分10
5秒前
儒_关注了科研通微信公众号
7秒前
linlin发布了新的文献求助10
7秒前
9秒前
10秒前
11秒前
赘婿应助Frequently2012采纳,获得10
11秒前
Lucas应助geohr采纳,获得10
11秒前
katana完成签到,获得积分10
11秒前
wendy_1006完成签到,获得积分10
12秒前
13秒前
甜蜜鹭洋完成签到 ,获得积分10
14秒前
LY完成签到,获得积分10
15秒前
yufeizhle完成签到 ,获得积分10
15秒前
自觉紫安发布了新的文献求助10
15秒前
tesla发布了新的文献求助10
15秒前
天地一体完成签到,获得积分10
16秒前
在水一方应助Meiyu采纳,获得10
16秒前
17秒前
只影有你完成签到,获得积分10
19秒前
19秒前
韩小小发布了新的文献求助10
23秒前
艺艺子完成签到,获得积分10
23秒前
ding应助kosotoki采纳,获得50
24秒前
虚拟的柜子完成签到,获得积分10
26秒前
Chris完成签到,获得积分10
26秒前
勤恳马里奥应助LY采纳,获得10
28秒前
glanceofwind完成签到 ,获得积分10
28秒前
自觉紫安完成签到,获得积分10
29秒前
32秒前
32秒前
jingyi完成签到,获得积分10
34秒前
34秒前
LIN完成签到,获得积分10
35秒前
36秒前
冷静剑成发布了新的文献求助30
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Rapid Review of Electrodiagnostic and Neuromuscular Medicine: A Must-Have Reference for Neurologists and Physiatrists 1000
François Ravary SJ and a Sino-European Musical Culture in Nineteenth-Century Shanghai 500
The Handbook of Communication Skills 500
求中国石油大学(北京)图书馆的硕士论文,作者董晨,十年前搞太赫兹的 500
基于3um sOl硅光平台的集成发射芯片关键器件研究 500
Educational Research: Planning, Conducting, and Evaluating Quantitative and Qualitative Research 460
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4796034
求助须知:如何正确求助?哪些是违规求助? 4116540
关于积分的说明 12735255
捐赠科研通 3846239
什么是DOI,文献DOI怎么找? 2119631
邀请新用户注册赠送积分活动 1141688
关于科研通互助平台的介绍 1031146